On September 17, 2020, Athira Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, priced its initial public offering of 12 million shares of its common stock at $17.00 per share. All shares were offered by Athira. The gross proceeds are expected to be $204 million, before deducting underwriting discounts and commissions and estimated offering expenses. Wilson Sonsini represented Athira in connection with the offering. 

The shares began trading on September 18, 2020, on the Nasdaq Global Select Market under the ticker symbol “ATHA.” The sale of the 12 million shares closed on September 22, 2020. Athira also granted the underwriters a 30-day option to purchase up to an additional 1.8 million shares of its common stock at the initial public offering price, less underwriting discounts and commissions.

The offering was led by Goldman Sachs & Co. LLC, Jefferies, and Stifel, with JMP Securities acting as co-manager.

Based in Seattle, Washington, Athira Pharma is in late-stage clinical development for its lead therapeutic candidate called ATH-1017, a drug being developed for the treatment of Alzheimer’s disease.

The Wilson Sonsini corporate team advising Athira includes partners Michael Nordtvedt, Bryan King, and Donna Petkanics; associates Laura Duncan, and Ashley Schmidt; and senior paralegal Barbara Mery.

For more information, please see Athira Pharma’s news release.